Stockreport

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Dis...

Harrow, Inc.  (HROW) 
Last harrow, inc. earnings: 11/13 04:21 pm Check Earnings Report
PDF VEVYE® Offers Rapid Onset with Clinically and Statistically Meaningful ImprovementBeginning as Early as 15 Days1 with Sustained Improvement over 56 Weeks2VEVYE® Patients [Read more]